Articles

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

The Icahn School of Medicine at Mount Sinai, New York, NY, USA
University of Michigan Cancer Center, Ann Arbor, MI, USA
Princess Margaret Cancer Centre, Toronto, ON, Canada
St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA
University of California, Los Angeles, CA, USA
Cross Cancer Institute Edmonton, AB, Canada
Monash University, VIC, Australia
Winship Cancer Institute, Emory University, Atlanta, GA, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
The Icahn School of Medicine at Mount Sinai, New York, NY, USA
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 102 No. 2 (2017): February, 2017 https://doi.org/10.3324/haematol.2016.151126